Market capitalization | $1.35b |
Enterprise Value | $932.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 16.53 |
P/S ratio (TTM) P/S ratio | 23.99 |
P/B ratio (TTM) P/B ratio | 3.40 |
Revenue growth (TTM) Revenue growth | -17.76% |
Revenue (TTM) Revenue | $56.42m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
18 Analysts have issued a Nurix Therapeutics Inc forecast:
18 Analysts have issued a Nurix Therapeutics Inc forecast:
Aug '24 |
+/-
%
|
||
Revenue | 56 56 |
18%
18%
|
|
Gross Profit | 41 41 |
27%
27%
|
|
EBITDA | -178 -178 |
22%
22%
|
EBIT (Operating Income) EBIT | -194 -194 |
22%
22%
|
Net Profit | -177 -177 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Arthur Sands |
Employees | 284 |
Founded | 2009 |
Website | www.nurixtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.